| Bioactivity | Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM[1]. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface[2]. | ||||||
| Invitro | Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with a IC50 of 0.94 nM[1]. [66Ga]DOTA-E-[c(RGDfK)]2 can be prepared with high radiochemical purity (>97%), specific activity (36-67GBq/μM), in vitro stability, and moderate protein binding. MicroPET imaging up to 24 post-injection showed contrasting tumors reflecting αvβ3-targeted tracer accumulation[2]. | ||||||
| Name | Cyclo(-RGDfK) | ||||||
| CAS | 161552-03-0 | ||||||
| Shortening | Cyclo(RGDFK) | ||||||
| Formula | C27H41N9O7 | ||||||
| Molar Mass | 603.67 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
Cyclo(-RGDfK)
CAS: 161552-03-0 F: C27H41N9O7 W: 603.67
Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) TFA pot
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.